Insomnia Severity Index, Nicotine Insomnia, and Seasonal Patterns

The insomnia severity index is a validated 7-item questionnaire that quantifies insomnia symptoms on a 0 to 28 scale, with scores above 14 indicating moderate insomnia warranting clinical assessment. Nicotine insomnia occurs because nicotine acts as a stimulant on nicotinic acetylcholine receptors that overlap with the arousal circuitry, shortening sleep onset and reducing total sleep time at doses as low as a single cigarette within 60 minutes of bed. Anemia insomnia arises through a different mechanism: iron deficiency specifically increases the frequency of restless leg syndrome symptoms and periodic limb movements during sleep, fragmenting sleep architecture even when sleep onset is normal. Seasonal insomnia describes the pattern where sleep difficulty worsens during specific times of year, most commonly autumn and winter in regions above 40 degrees latitude, driven by reduced light exposure and circadian misalignment. Coq10 insomnia represents a less common but documented phenomenon where high-dose CoQ10 supplementation causes sleep onset difficulty through its stimulatory effect on mitochondrial energy production.

This guide covers each of these insomnia types and their measurement, mechanisms, and management.

Using the Insomnia Severity Index

Scoring and Clinical Interpretation

The insomnia severity index asks about difficulty falling asleep, staying asleep, and early waking, plus satisfaction with sleep, daytime impairment, and how noticeable the problem is to others. Each item is scored 0 to 4, and the total determines insomnia severity: 0 to 7 is no clinically significant insomnia, 8 to 14 is subthreshold insomnia, 15 to 21 is moderate clinical insomnia, and 22 to 28 is severe insomnia. The questionnaire takes approximately 5 minutes to complete and is freely available in the public domain.

Clinicians use the insomnia severity index as both a diagnostic screener and a treatment outcome measure. A score reduction of 6 or more points between baseline and follow-up assessments is considered a clinically meaningful response to CBT-I or pharmacological treatment. Many sleep clinics administer it at every visit to track progress with the same rigor used for blood pressure or HbA1c in chronic disease management.

Nicotine, Anemia, and CoQ10 Insomnia Mechanisms

Nicotine insomnia is dose- and timing-dependent. Smoking within 60 minutes of sleep onset raises sleep onset latency by an average of 13 minutes compared to smoke-free evenings in regular smokers, and reduces N3 slow-wave sleep time by 10 to 15 percent. Nicotine withdrawal also causes insomnia: users who quit abruptly experience heightened arousal, vivid dreaming, and fragmented sleep for 1 to 2 weeks, a pattern that NRT (nicotine replacement therapy) patches help moderate if applied at reduced doses that do not maintain daytime nicotine levels into the sleeping hours.

Anemia insomnia, specifically in iron-deficiency anemia, relates to reduced central dopamine availability — iron is a cofactor for dopamine synthesis, and dopamine regulates the spinal inhibitory circuits that prevent restless leg symptoms. Treating iron deficiency to a ferritin level above 50 mcg/L resolves or substantially reduces restless leg syndrome and associated insomnia in iron-deficient patients within 4 to 8 weeks of supplementation.

Coq10 insomnia occurs primarily with doses above 200 mg taken in the afternoon or evening. CoQ10 increases mitochondrial electron transport efficiency, which produces a mild stimulant effect. Taking CoQ10 with or before lunch (before 2 PM) eliminates the sleep disruption for most users while preserving the cardiovascular and energy metabolism benefits.

Seasonal Insomnia Management

Seasonal insomnia caused by reduced autumn and winter light exposure responds to morning bright light therapy using a 10,000 lux lamp for 20 to 30 minutes within 30 minutes of waking. This light exposure advances the circadian clock toward earlier timing, counteracting the phase-delay tendency that low-light seasons produce. Consistent treatment over 2 to 4 weeks reduces both insomnia severity index scores and mood symptoms in seasonal patterns.

Next Steps

Complete an insomnia severity index questionnaire to establish a baseline score before initiating any treatment. Score 8 to 14: focus on sleep hygiene and stimulus control. Score 15 or above: consider CBT-I referral alongside addressing any identifiable contributors such as nicotine timing, iron status testing, or seasonal light therapy. Retest with the insomnia severity index at 4 and 8 weeks to objectively track whether interventions are producing meaningful improvement.